?Dapagliflozin Tetraacetate | SGLT2 Inhibitor Intermediate? ??
High-Purity Pharmaceutical API for Diabetes Drug Synthesis

?? ?Product Overview?

Dapagliflozin Tetraacetate is a critical intermediate in the synthesis of ?dapagliflozin?, a leading SGLT2 inhibitor used globally to treat type 2 diabetes by regulating blood glucose levels?13. It serves as a high-purity active pharmaceutical ingredient (API) for formulating oral antidiabetic medications and advanced pharmaceutical intermediates?23.

?Key Applications?:

• Diabetes drug manufacturing ??

• Pharmaceutical R&D laboratories ??

• Bulk API production for metabolic therapies ??

? ?Key Advantages?

?? ?Applications?

1. ?Diabetes Therapeutics?

   : Core intermediate for dapagliflozin API synthesis?34.

2. ?Pharmaceutical Research?

   : Used in preclinical studies for novel SGLT2 inhibitors?12.

3. ?API Manufacturing?

   : Integrated into GMP-compliant production lines?23.

?? ?Quality Certifications?

• Manufactured under ?GMP? and ?ISO 9001? guidelines?.

• Tested via ?HPLC, GC-MS?, and residual solvent analysis?.

• Full ?COA? (Certificate of Analysis) provided per batch?.

?? ?Market Trends?

The global SGLT2 inhibitor market is projected to grow at ?8.2% CAGR (2025-2030)?, driven by rising diabetes prevalence and demand for precision therapies?13. Dapagliflozin remains a top-tier drug, with API intermediates like Dapagliflozin Tetraacetate seeing ?15% annual demand growth??34.